Testosterone Cypionate vs Jatenzo: Switching Between Them

What Are These Two Drugs and How Do They Work?

Testosterone cypionate is an esterified testosterone delivered by intramuscular or subcutaneous injection, producing a depot that releases testosterone over approximately 7 to 14 days. Jatenzo is an oral testosterone undecanoate absorbed via intestinal lymphatics, bypassing first-pass hepatic metabolism. Both raise serum testosterone, but the delivery mechanisms create meaningfully different pharmacokinetic profiles, side-effect considerations, and lifestyle trade-offs.

Testosterone Cypionate: Mechanism and Pharmacokinetics

After injection, the cypionate ester is cleaved by tissue esterases, releasing free testosterone. Peak serum levels typically appear within 24 to 72 hours, then decline toward baseline by day 10 to 14. This produces the classic "peak-and-trough" pattern many patients notice as energy fluctuations near the end of each injection interval. FDA prescribing information for testosterone cypionate lists a half-life of approximately 8 days for the ester.

Weekly dosing at 100 mg or biweekly dosing at 200 mg are the most common clinical schedules. Subcutaneous administration at lower weekly doses (50 to 70 mg) is increasingly used in telehealth settings to flatten the peak-trough swing and reduce the hematocrit rise that comes with supraphysiologic peaks.

Jatenzo: Mechanism and Pharmacokinetics

Jatenzo (testosterone undecanoate in a lipid formulation) is absorbed through intestinal lymphatics as chylomicrons, entering the bloodstream without passing through the liver. This is why it avoids the hepatotoxicity associated with 17-alpha-alkylated oral androgens. Half-life is short, roughly 1.6 to 2 hours, which is why the drug is dosed twice daily with meals. FDA Jatenzo prescribing information specifies the starting dose as 237 mg twice daily, with titration based on mid-dose serum testosterone drawn 6 hours after the morning dose. Fat content in the meal significantly affects absorption, so a consistent dietary fat intake is required for stable levels.

Efficacy: What Do the Trial Data Show?

No published randomized trial has directly compared testosterone cypionate injections with Jatenzo oral capsules head-to-head. The evidence base for each drug comes from separate key studies, and cross-trial comparisons must be made cautiously.

T-Trials Evidence for Injectable Testosterone

The Testosterone Trials (T-Trials), reported in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 or older with serum testosterone below 275 ng/dL. Participants received either testosterone gel (1.62%) or placebo for 12 months. Sexual function, vitality, physical function, and mood were co-primary endpoints across seven coordinated trials. T-Trials results published in NEJM showed statistically significant improvements in sexual function (P<0.001), self-reported vitality (P<0.001), and 6-minute walk distance compared with placebo. While the T-Trials used gel rather than cypionate injections, the testosterone produced in treated subjects reached the same eugonadal target range used in injectable protocols, making the symptomatic outcomes relevant to the clinical question of what normalized testosterone does. Injectable cypionate achieves equivalent or higher peak serum levels than gel at standard doses.

Swerdloff 2020: Jatenzo Key Trial

Swerdloff et al., published in the Journal of Clinical Endocrinology and Metabolism in 2020, was the primary registration trial for Jatenzo. The 12-week open-label study enrolled men with hypogonadism and titrated oral testosterone undecanoate to achieve a serum total testosterone of 300 to 1000 ng/dL. Swerdloff et al. 2020 in J Clin Endocrinol Metab reported that 87% of subjects reached normal serum testosterone at the 3-month mark after dose titration. Mean serum total testosterone on treatment was approximately 421 ng/dL, a mid-normal result consistent with the drug's twice-daily dosing keeping levels steadier than a weekly injection would. Diastolic blood pressure increased by a mean of 3.2 mmHg and systolic by 4.9 mmHg, findings that drove the FDA black-box warning.

Side-by-Side Efficacy Summary

Both drugs raise testosterone into the normal range in the majority of patients. Jatenzo's 87% normalization rate at 3 months is a specific registered-trial figure. Published real-world data on cypionate show normalization rates above 80% when dosing is individualized, though the peak-trough variability means some trough draws fall below 300 ng/dL even when average levels are adequate. Clinicians often draw cypionate labs at trough (just before the next injection) to identify patients who need more frequent dosing rather than higher doses.

Safety Profiles: Where the Two Drugs Differ Most

Cardiovascular Risk and Blood Pressure

The most clinically meaningful safety difference is the blood pressure signal for Jatenzo. The FDA label for Jatenzo carries a black-box warning stating that the drug can increase blood pressure and that it should not be used in men with uncontrolled hypertension. The prescribing information requires blood pressure monitoring prior to starting, at 3 to 6 weeks, and then periodically. This concern does not carry a black-box designation for testosterone cypionate, though all testosterone formulations may modestly raise blood pressure via sodium retention and erythrocytosis.

Men with pre-existing hypertension, stage 2 hypertension, or multiple cardiovascular risk factors are generally poorer candidates for Jatenzo than for cypionate, where the smaller dose-per-administration and subcutaneous routes can limit peak-driven erythrocytosis.

Erythrocytosis and Hematocrit

Testosterone stimulates erythropoiesis via EPO-dependent and EPO-independent pathways. Both formulations raise hematocrit, though the risk is higher with injectables that produce supraphysiologic peaks. Most guidelines recommend holding dose or adjusting frequency if hematocrit exceeds 54%. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends checking hematocrit at baseline, 3 to 6 months, and annually. This applies to both cypionate and Jatenzo.

Hepatotoxicity

Jatenzo is not hepatotoxic at therapeutic doses because it avoids first-pass liver metabolism through lymphatic absorption. Testosterone cypionate at standard doses is also not hepatotoxic. Older concerns about oral androgens came from 17-alpha-alkylated compounds such as methyltestosterone, which are unrelated to either of these drugs.

Injection Site vs. GI Tolerability

Testosterone cypionate requires either self-injection or clinic visits every 7 to 14 days. Some patients experience injection site discomfort, sterile nodules with subcutaneous administration, or needle anxiety. Jatenzo eliminates injections entirely but requires strict twice-daily dosing with meals and can cause GI discomfort in some patients. Missing a dose or taking it without adequate dietary fat leads to erratic absorption and subtherapeutic levels.

Dosing and Titration: Practical Details

Testosterone Cypionate Dosing

Standard starting doses in hypogonadal men are 100 mg intramuscularly once weekly or 200 mg every two weeks. Subcutaneous dosing at 50 to 70 mg weekly is gaining traction in telehealth-based TRT because it produces flatter serum testosterone curves and may reduce hematocrit elevation compared with intramuscular injection. FDA-approved labeling for testosterone cypionate injection does not specify subcutaneous use, but peer-reviewed pharmacokinetic studies have validated this route.

Trough levels (drawn immediately before the next injection) should target 400 to 700 ng/dL for most men. If trough levels fall below 300 ng/dL, increasing injection frequency (from every 14 days to every 10 or 7 days) is preferable to doubling the dose, which raises peak levels and erythrocytosis risk.

Jatenzo Dosing

The FDA-approved starting dose is 237 mg twice daily with food. After 3 to 6 weeks, a mid-dose serum testosterone (drawn 6 hours after the morning dose, before the evening dose) guides titration. If the mid-dose level is below 400 ng/dL, the dose increases to 316 mg (one 237 mg plus one 79 mg capsule) twice daily, then to 396 mg twice daily if still inadequate. Approximately 35% of patients in the Swerdloff trial required a dose increase beyond the starting 237 mg twice daily to reach normal testosterone Swerdloff et al. 2020.

Switching Between Testosterone Cypionate and Jatenzo

No published clinical protocol exists for converting between these two specific formulations. The framework below is derived from first principles of pharmacokinetics and general TRT switching guidance.

Switching From Testosterone Cypionate to Jatenzo

Testosterone cypionate has a half-life of approximately 8 days. After the last injection, serum testosterone will fall progressively over roughly 3 to 4 weeks. You do not need to wait for full washout before starting Jatenzo. A practical approach used in clinical practice is to start Jatenzo at the standard 237 mg twice-daily dose 7 days after the last cypionate injection. This prevents a prolonged gap in testosterone coverage while allowing cypionate levels to begin declining before oral dosing establishes its own steady state.

Draw a mid-dose serum testosterone 3 to 6 weeks after the switch to Jatenzo to confirm the new formulation is achieving eugonadal levels. Check blood pressure at baseline and again at weeks 3 to 6, per the Jatenzo black-box warning.

Before starting Jatenzo, confirm blood pressure is controlled. Men with a systolic blood pressure above 140 mmHg or diastolic above 90 mmHg should not start Jatenzo without managing hypertension first, per FDA label guidance.

Switching From Jatenzo to Testosterone Cypionate

Because Jatenzo has a half-life of only 1.6 to 2 hours, levels fall to near zero within 12 hours of the last dose. Starting testosterone cypionate the day after the last Jatenzo dose is reasonable. Begin with 100 mg intramuscularly or subcutaneously weekly. Draw trough levels at week 4 to assess the starting dose.

Patients switching from Jatenzo to cypionate because of blood pressure concerns should have blood pressure monitored at 4 weeks post-switch; cypionate is unlikely to resolve existing hypertension, but the blood pressure rise specific to Jatenzo's lymphatic absorption peak should diminish within days of stopping oral therapy.

Why Patients Switch: Common Clinical Scenarios

Patients switching from cypionate to Jatenzo most often cite needle aversion, travel convenience, or difficulty maintaining injection schedules. Patients switching in the opposite direction typically cite cost, meal-timing inconvenience, or blood pressure concerns. Generic testosterone cypionate costs roughly 30 to 50 dollars per month at most pharmacies. Jatenzo's list price exceeds 500 dollars monthly without insurance, making cost a real barrier for many patients. The American Urological Association's 2018 testosterone deficiency guideline acknowledges that patient preference and lifestyle factors are legitimate inputs into formulation selection, not secondary to clinical efficacy alone.

Who Is the Better Candidate for Each Drug?

Testosterone Cypionate: Preferred When

Testosterone cypionate is generally preferred for men who are comfortable with self-injection, who have pre-existing hypertension or significant cardiovascular risk, who cannot tolerate twice-daily medication schedules, and for whom cost is a meaningful concern. It is also preferable when hematocrit is already borderline high, because subcutaneous low-dose weekly administration can be fine-tuned to keep erythropoietic stimulation lower than a high-peak intramuscular protocol.

Jatenzo: Preferred When

Jatenzo is a reasonable first choice for men with needle aversion, men whose occupations or lifestyles involve erratic meal schedules (provided they can commit to consistent fat intake twice daily), and men who have had difficulty maintaining stable injection schedules. It may also be preferred in men who have injection-site complications such as persistent nodules or sterile abscesses. Blood pressure must be controlled before starting.

The Endocrine Society's Position on Formulation Choice

The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism states: "We suggest that clinicians offer [testosterone] therapy only to men who have symptoms and signs consistent with testosterone deficiency and who have unequivocally low serum testosterone concentrations." Endocrine Society guideline 2018 does not mandate a specific formulation but instructs clinicians to select based on patient preference, cost, formulation-specific risks, and monitoring feasibility. The blood pressure warning specific to Jatenzo means that cardiovascular risk stratification should occur before prescribing.

Monitoring Requirements for Both Formulations

Both testosterone cypionate and Jatenzo require the same core monitoring panel: serum total testosterone, hematocrit, PSA, and liver function tests at baseline. Subsequent monitoring schedules differ slightly.

Cypionate Monitoring Schedule

Draw trough serum testosterone (just before next injection) at 4 and 12 weeks after starting or changing dose. Check hematocrit at 3 to 6 months, then annually. PSA at 3 to 6 months, then per age-appropriate prostate cancer screening guidelines. Endocrine Society 2018 recommends checking testosterone at trough for injections to avoid sampling during a peak that might overestimate average exposure.

Jatenzo Monitoring Schedule

Draw mid-dose serum testosterone (6 hours after morning dose) at weeks 3 to 6, then after any dose change. Check blood pressure at baseline, 3 to 6 weeks, and periodically thereafter per the FDA black-box warning. Hematocrit at 3 months, then annually. PSA follows the same schedule as for cypionate.

Cost and Insurance Considerations

Testosterone cypionate is available as a generic and is one of the lowest-cost TRT formulations available. A 10 mL multi-dose vial (200 mg/mL) typically costs 30 to 60 dollars at retail pharmacies, enough for approximately 2 to 5 months of therapy depending on dose. Most commercial insurance plans cover it with minimal prior authorization.

Jatenzo remains brand-only with no generic equivalent as of mid-2025. Retail pricing runs approximately 500 to 700 dollars monthly. Coverage under commercial insurance is inconsistent and often requires documentation of failure on at least one other formulation. The prescribing clinician should confirm prior authorization requirements before switching a patient to Jatenzo from cypionate, because a coverage denial mid-treatment creates an unwanted gap.

Practical Patient Instructions for the Switch

Patients switching from testosterone cypionate to Jatenzo should receive written instructions covering five points. Take the first Jatenzo dose 7 days after the last cypionate injection. Take each dose with a meal containing at least 30 grams of fat. Measure and record blood pressure at home daily for the first 4 weeks. Return for a mid-dose serum testosterone draw at week 4 to 6. Report headache, blurred vision, or any blood pressure reading above 150/95 mmHg immediately.

Patients switching from Jatenzo to testosterone cypionate should start the first injection within 24 hours of the last oral dose. Begin at 100 mg weekly regardless of previous Jatenzo dose. Return for a trough testosterone draw at 4 weeks to guide dose adjustment.